QLUPOD AG: Qlupod AG completes capital increase and strengthens financial base

Herisau (pta019/23.01.2026/16:03 UTC+1)

Herisau, Switzerland – Qlupod AG, January 22, 2026 (www.qlupod.com)

Qlupod AG has successfully completed its most recent capital increase. The registration

in the Swiss Commercial Register became effective on January 20, 2026. The newly

issued shares have been duly created and recorded in the company's digitized share

register.

In addition to strengthening its equity base, the capital increase also allowed for the

reduction of existing liabilities through offsetting. This has further improved the

company's balance sheet structure and increased its financial flexibility.

The current share offering price of CHF 4.35 remains unchanged. Since the last

company valuation in November 2023, Qlupod AG has made significant operational,

technological, and strategic progress. The ongoing financing round is primarily focused

on expanding distribution and marketing activities as well as preparing the company for

its next growth phase.

A strategic priority is the preparation for a potential market entry into the United States.

In parallel, the company continues discussions with both existing and prospective new

investors.

The current financing round, with a remaining target volume of CHF 2.4 million, is

planned to be completed by the end of April. Subject to its successful completion, the

company expects to reach operational break-even by the end of 2026 at the latest.

Based on this development, Qlupod AG is reviewing long-term strategic options,

including the potential preparation for an initial public offering (IPO).

About Qlupod:

Qlupod AG is a start-up company in the field of telemedicine and develops innovative

solutions to make patient care efficient and cost-effective. With the QluPod device and

the associated software, the company is endeavouring to shape the future of healthcare.

The offering is aimed at hospitals, care facilities, medical professionals and private

individuals who want to monitor their health independently.

For more information about Qlupod AG and our products, please visit our website at

www.qlupod.com.

Disclaimer:

This publication constitutes neither an offer to sell nor a solicitation to buy securities.

Insofar as this document contains forward-looking statements, these do not represent

facts and are characterised by the words "expect", "believe", "estimate", "intend", "aim",

"assume" and similar expressions. These statements express the intentions, opinions or

current expectations and assumptions of Qlupod AG and are based on current plans,

estimates and forecasts which Qlupod AG has made to the best of its knowledge, but do

not claim to be correct in the future. Forward-looking statements are subject to risks anduncertainties that are difficult to predict and are generally beyond the control of Qlupod

AG. It should be noted that actual events or developments may differ materially from

the events and developments expressed or implied by such forward-looking statements.

(end)

Emitter:	QLUPOD AG Bahnhofstrasse 23 9100 Herisau Switzerland
Contact Person:	Nikola Trajanov
Phone:	+41 71 510 05 45
E-Mail:	ir@qlupod.com
Website:	qlupod.eu
ISIN(s):	CH1222316429 (Share)
Stock Exchange(s):	-
Other Stock Exchanges:	Regelmaessige Kursfeststellung Schweiz